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634 © 2019 The British Pharmacological SociAlcohol use disorder is associated with several mental, physical, and social problems.
Its treatment is difficult and often requires a combination of pharmacological and
behavioural therapy. The brain histaminergic system, one of the wake‐active systems
that controls whole‐brain activity, operates through three neuronal GPCRs. The
histamine H3 receptor (Hrh3), which is expressed in many brain areas involved in
alcohol drinking and alcohol reward, can be targeted with a number of drugs devel-
oped initially for cognitive disorders and/or disorders related to sleep, wakefulness,
and alertness. In all rodent alcohol drinking models tested so far, H3 receptor
antagonists have reduced alcohol drinking and alcohol‐induced place preference and
cue‐induced alcohol reinstatement. Several H3 receptor antagonists tested and found
to be safe for humans could be subjected to clinical tests to treat alcohol use disorder.
Preference should be given to short‐acting drugs to avoid the sleep problems associ-
ated with the wake‐maintaining effects of the drugs.
LINKED ARTICLES: This article is part of a themed section on New Uses for 21st
Century. To view the other articles in this section visit http://onlinelibrary.wiley.
com/doi/10.1111/bph.v177.3/issuetoc1 | ALCOHOL AND BRAIN
NEUROTRANSMITTER SYSTEMS
Alcohol use disorder (AUD) is a complex disease, which is despite
recent developments still a major health problem (Abrahao, Salinas,
& Lovinger, 2017). Drug treatments, based on known targets or
circuits, including those tested or already in use (disulphiram, naltrex-
one, acamprosate, topiramate, baclofen, and gabapentin) all require
complementary behavioural therapy, and the results are often still
not satisfactory (Abrahao et al., 2017; Korpi et al., 2015; Vuoristo‐
Myllys, Lipsanen, Lahti, Kalska, & Alho, 2014).
The brain histaminergic system in mammals comprises cell bodies in
the posterior basal hypothalamus in an area named the tuberomamillary
nucleus (TMN; Panula, Airaksinen, Pirvola, & Kotilainen, 1990; Panula,ng rat); ANA, ALKO non‐alcohol
rder; NAcc, nucleus accumbens;
tuberomamillary nucleus; VTA,
ety wileyonlineYang, & Costa, 1984; Watanabe et al., 1984), which sends projections to
all major parts of the brain (Inagaki et al., 1988; Panula, Pirvola, Auvinen,
& Airaksinen, 1989). Alcohol is a simple compound that interacts with tar-
get cells mainly through hydrogen bonding and weak hydrophobic inter-
actions (Abrahao et al., 2017) in addition to specific neurotrasnmitter
receptors, and thus, high concentrations are needed for reinforcing
and sedative effects. Most brain areas are thus affected by systemic
intake of alcohol, which affects cells and circuits in many brain areas that
receive histaminergic innervation (Inagaki et al., 1988; Panula, Pirvola,
Auvinen, & Airaksinen, 1989). Alcohol has well‐characterized effects
on GABA and glycine receptors and less well‐understood effects at the
glutamate NMDA receptor (Abrahao et al., 2017; Korpi et al., 2015).
Since these receptors and some of the signalling pathways also directly
affected by alcohol are found in many aminergic neurons, these neurons
are among the direct or indirect targets of alcohol.
Initial acute effects of alcohol include increased inhibition through
GABAA receptor potentiation, reduced excitation through block of NMDA
and AMPA receptors, activation of the mesolimbic system throughBr J Pharmacol. 2020;177:634–641.library.com/journal/bph
PANULA 635BJPincreased dopamine release, and effects (relaxation, euphoria, and
anxiolysis) mediated by neuropeptide systems (Korpi et al., 2015). With-
drawal symptoms are associated with reduced GABAA receptor signalling,
increased excitation mediated by NMDA and AMPA receptor activation,
and reduced dopamine release in the mesolimbic system. These plastic
changes affect a number of brain areas, including the orbitofrontal and pre-
frontal cortex, dorsomedial, dorsolateral and ventral striatum (nucleus accum-
bens [Acb]), lateral habenula, amygdala, bed nucleus of the stria terminalis,
substantia nigra (SN), ventral tegmentum, and some brainstem areas.
Although none of the well‐known behavioural effects of alcohol are directly
linked to the histaminergic neuron system, many of these areas express high
levels of at least one of the three neuronal G‐protein‐coupled histamine
receptors, postsynapticH1 receptor, H2 receptor, or pre or postsynaptic H3
receptor (Hrh3). In the neurons that express H3 receptors, neurotransmitter
release is likely affected by histamine through this receptor or by constitutive
activity of the H3 receptor (Panula et al., 2015).
2 | GPCRs AS TARGETS FOR AUD
GPCRs are among the most utilized drug targets. Not surprisingly, several
GPCRs have been tested in rodents as potential targets to treat AUD.
Selective receptor agonists and antagonists and gene‐modified animals
have been used in these experiments. Since several methods have been
used with variable controls, the results have not always been easy to
interpret. Among the most studied receptor are the opioid receptors
(Contet, Kieffer, & Befort, 2004; Matthes et al., 1996), dopamine
D1 and D2 receptors (Cunningham et al., 2000; El‐Ghundi et al., 1998),
5‐HT receptors (Crabbe et al., 1996; de Bruin et al., 2013),metabotropic
glutamate receptors (Zhou et al., 2013), cannabinoid receptors
(Hungund, Szakall, Adam, Basavarajappa, & Vadasz, 2003; Naassila,
Pierrefiche, Ledent, & Daoust, 2004), and muscarinic receptors (de la
Cour et al., 2015). Indeed, repeated alcohol administration increases levels
of methionine encephalin‐Arg‐Phe levels in the periaqueductal gray
(Lindholm, Ploj, Franck, & Nylander, 2000), and acute moderate doses
induce release of methionine‐enkephalin in the NAcc (Marinelli, Bai,
Quirion, &Gianoulakis, 2005).Naltrexone, which preferentially blocks opi-
oid μ receptors, is one of the few accepted treatments for AUD. Naltrex-
one decreases alcohol consumption in rhesus monkeys (Altshuler, Phillips,
& Feinhandler, 1980) and rats (Stromberg, Casale, Volpicelli, Volpicelli, &
O'Brien, 1998) and is one of the few available drugs currently accepted
for treatment of AUDdespite challengesmetwhen treating heavy drinkers
(Vuoristo‐Myllys, Lahti, Alho, & Julkunen, 2013). The H3 receptor was not
initially among the targets predicted to treat AUD, but the findings on a
robust reduction in alcohol drinking in both rats (Lintunen et al., 2001)
and mice (Nuutinen, Karlstedt, Aitta‐Aho, Korpi, & Panula, 2010) were ini-
tially unexpected, but have since been independently verified.
3 | HISTAMINE AND H3 RECEPTORS IN
BRAIN AREAS RELEVANT FOR AUD
The H3 receptor is widely expressed in the brain of all vertebrates studied
(Pillot et al., 2002; Sallmen, Lozada, Anichtchik, Beckman, & Panula, 2003;
Sundvik et al., 2011; Tardivel‐Lacombe et al., 2000). In rat brain, thedifferent isoforms show slightly different expression patterns (Drutel
et al., 2001), but the significance of this and detailed roles of the isoforms
are not known. In general, the H3 receptor is expressed in histaminergic
neurons, which is in agreement with its role as an autoreceptor, and in
many brain regions. One of the most consistent findings is its abundant
expression in telencephalic structures (Figure 1), such as the striatum
and cerebral cortex, and dorsal thalamus (Jin, Kalimo, & Panula, 2002; Jin
& Panula, 2005; Panula & Nuutinen, 2013; Panula, Sundvik, & Karlstedt,
2014). A comparison of H3 receptor mRNA and receptor radioligand bind-
ing studies and the knowledge of neuronal pathways suggests that
this receptor is found in several critically important brain structures and
pathways related to cognitive functions, motivation, aversion and plea-
sure, and locomotion, such as the thalamocortical, hypothalamocortical,
and striatonigral systems (Panula & Nuutinen, 2013; Figure 2). Both the
expression of this receptor and receptor radioligand binding are high in
limbic structures such as the hippocampus and amygdala (Haas & Panula,
2003). Interestingly, the tuberomamillary nucleus in which the histaminer-
gic neurons reside receives its heaviest innervation from the infralimbic or
medial prefrontal cortex in the rat (Ericson, Blomqvist, & Kohler, 1991),
suggesting that the histaminergic neurons get direct inputs from this brain
region, which is in a key area for decision making and executive functions.
The H3 receptor is highly expressed in this area of the brain.
Brain areas important in AUD include the mesocorticotriatal system
and extended amygdala including the nucleus of the stria terminalis and
habenula (Abrahao et al., 2017; Koob & Volkow, 2016; Korpi et al., 2015;
Figure 2). H3 receptor mRNA expression and receptor radioligand binding
are high in almost all of these areas (Figures 1 and 2), which render it diffi-
cult to identify a sole site of action of H3 receptor antagonists on alcohol
drinking or alcohol‐induced place preference. One of the few sites where
these drugs affect a significant signalling pathway for these behaviours is
the striatum, where an H3 receptor antagonist has been shown to regulate
dopaminergic signalling (Nuutinen et al., 2016). In the striatum, dopamine
receptor signallingwas increased by dopamine receptor agonistsquinpirole
and SKF38393 in wild type but not in H3 receptor knockout mice
(Kononoff Vanhanen, Nuutinen, Tuominen, & Panula, 2016). Even in this
location, several H3 receptor expressing pathways merge (Panula &
Nuutinen, 2013). Obviously, systemic administration of H3 receptor antag-
onists, which is also the most appropriate route for evaluating mechanisms
intended to be clinically relevant, affects all the circuits in the brain inwhich
the H3 receptor is active. The behavioural consequences of systemic
administration naturally represents the sum effect of all these targeted
brain areas and circuits. Site targeted administration schedules to study
the contribution of distinct H3 receptor‐expressing cell types have not
yet been applied to address alcohol‐related behaviours. Since these H3
receptor‐expressing cells release many other neurotransmitters regulated
by H3 receptors, the role of H3 receptor antagonists in alcohol‐related
behaviours is likely due to circuits involving many of these transmitters.
4 | ALCOHOL AND HISTAMINE–DOPAMINE
INTERACTIONS
The ventral tegmentum, which harbors dopaminergic and GABAergic
neurons, is crucial for the development of alcohol‐related behaviours:
FIGURE 1 In situ hybridization of rat brain sections with 35S‐labelled
oligonucleotide probes for histamine H3 receptor at (a) 2.70, (b) 0.70,
and (c) −3.60 mm from bregma shows a clear laminar expression of H3
receptor mRNA in various parts of the cortex (infralimbic cortex [IL],
cingulate cortex area 1 [Cg1], frontal cortex, area 1 [Fr1], frontal
cortex, area 3 [Fr3], and occipital cortex [Oc]) and high expression
throughout the caudate‐putamen (striatum; CPu) and nucleus
accumbens (Acb). IL and Cg1 represent parts of rat brain area thought
to correspond to parts of prefrontal cortex in humans. BL: basolateral
amygdaloid nucleus; CA1: field 1 of cornu ammonis in hippocampus;
Cg2: cingulate cortex area 2; VPM: ventral posteromedial thalamic
nucleus
636 PANULABJPan injection of the opioid antagonist methylnaloxonium (a non‐
selective opioid antagonist) or baclofen (a GABAB receptor agonist)
into the ventral tegmental area (VTA) but not into the NAcc decreasesalcohol‐induced place preference (Bechtholt & Cunningham, 2005).
Wistar rats also self‐administer alcohol into the posterior VTA but
not the anterior VTA (Rodd‐Henricks, McKinzie, Crile, Murphy, &
McBride, 2000). In the VTA, a single dose of alcohol induces a long‐
lasting potentiation of GABAergic synapses in dopaminergic neurons
(Melis, Camarini, Ungless, & Bonci, 2002).
Alcohol increases the firing of VTA dopaminergic neurons in both
C57BL/6J and DBA/2J mice (Brodie & Appel, 2000). Alcohol also
increases postsynaptic GABAA receptor sensitivity and enhances action
potential‐independent GABA release onto VTA dopaminergic neurons
(Theile, Morikawa, Gonzales, & Morrisett, 2008), which in turn may limit
the direct excitation of these neurons. The role ofH3 receptors in the reg-
ulation of VTA dopaminergic neurons may be complex: Local GABAergic
neurons and afferents from the NAcc are potential direct targets of H3
receptor antagonists, since the expression of H3 receptors in NAcc is
abundant and VTA GABAergic cells may form the population that
expresses H3 receptors. In addition, 5‐HT through 5‐HT2C receptors
modulates GABA release on dopaminergic neurons (Theile, Morikawa,
Gonzales, & Morrisett, 2009), and H3 receptor agonists inhibit
electrically‐evoked 5‐HT release at least in the SN (Threlfell et al.,
2004). Although it is possible that one of the key sites of H3 receptor
ligands’ action on alcohol‐related behaviours is the VTA, this is unlikely
because of the sparsity of H3 receptor radioligand binding and gene
expression in this region compared to the SN (Pillot et al., 2002).
During the operant alcohol self‐administration procedure, dopa-
mine release in the NAcc increases in both trained rats and handling
controls during placement in the operant chamber, but only in
alcohol‐consuming rats during alcohol but not water self‐
administration (Doyon et al., 2003). Intraperitoneal alcohol also
increases dopamine release in the posterior VTA in rats (Deehan
et al., 2016). In mice, alcohol increases dopamine release in the NAcc
without affecting histamine release (Nuutinen et al., 2016).
The location of the H3 receptor in many aminergic neurons allows
its release from terminals to be directly regulated by histamine and H3
receptor ligands (for a review, see Panula & Nuutinen, 2013). Although
in vitro evidence suggests that histamine inhibits the electrically‐
evoked release of [3H] dopamine from striatal slices in a manner that
is abolished by the H3 receptor antagonist thioperamide and thus
may suggest the presence of presynaptic H3 receptors on striatal
dopaminergic terminals (Schlicker, Fink, Detzner, & Gothert, 1993),
in vivo microdialysis has not revealed an evidence of dopamine release
in the striatum by H3 receptor antagonists (Aquino‐Miranda,
Escamilla‐Sanchez, Gonzalez‐Pantoja, Bueno‐Nava, & Arias‐Montano,
2016; Nuutinen et al., 2016). The H3 receptor antagonist
GSK189254 did not evoke the release of dopamine in the NAcc
(Giannoni et al., 2010), and ABT‐239, another H3 receptor antagonist,
induced the release of dopamine in the cortex but not the striatum
(Fox et al., 2005). Furthermore, the expression of H3 receptor mRNA
in the VTA and SN is low in rats and normal humans (Anichtchik,
Huotari et al., 2000; Anichtchik, Rinne et al., 2000; Drutel et al.,
2001), although H3 receptor radioligand binding is high in the SN
(Anichtchik et al., 2001; Anichtchik, Huotari et al., 2000; Pillot et al.,
2002). At the cellular level, the expression of H3 receptor mRNA has
FIGURE 2 Dopaminergic (blue) and
histaminergic (green) projections target many
brain areas essential in alcohol‐related
rewarding and drug‐seeking or aversive
behaviours. Dopaminergic projections to the
prefrontal cortex (PFC), nucleus accumbens
(Acb), and amygdala (Am) originate in the
ventral tegmental area (VTA); those directed
to the caudate‐putamen (CPu) originate in the
SN. All histaminergic projections originate in
the etuberomamillary nucleus (TMN). 5‐HT‐
containing dorsal raphe nucleus (DR; red) and
noradrenaline‐containing locus coeruleus (LC;
yellow) are also labelled, but their projections
are not included. The intensity of the grey
scale in target areas lateral habenular nucleus
(Lhb), PFC, CPu, Am, and Acb indicates the
intensity of the H3 receptor radioligand
binding density in autoradiographic films in rat
brain. SN: substantia nigra pars compacta
PANULA 637BJPbeen reported in the SN, although the transmitter phenotype of the
cells was not determined, whereas in the VTA, little if any H3 receptor
mRNA was detected (Pillot et al., 2002). Microarray analysis has not
verified H3 receptor gene (Hrh3) as one that distinguishes A9 and
A10 dopaminergic neurons (Chung et al., 2005), and the gene is not
among those which distinguish different clusters of mesencephalic
dopaminergic neurons (Poulin et al., 2014).
It is thus unlikely that H3 receptor antagonists would as such be
habit‐forming. The histaminergic neuron population may be heteroge-
neous, since H3 receptor antagonists administered intracerebrally
directly to the TMN induce the release of histamine from the prefron-
tal cortex and nucleus basalis magnocellularis but not from the NAcc
or dorsal striatum (Blandina, Munari, Provensi, & Passani, 2012).5 | H3 RECEPTOR, ALCOHOL DRINKING
AND CONDITIONED PLACE PREFERENCE
The first report on the possible role of H3 receptors in AUD was the
report by Lintunen et al. (2001) on alcohol‐preferring (AA) rats. In this
rat line, the levels and turnover of histamine in the brain were signifi-
cantly higher than those in the Wistar rats or alcohol non‐preferring
(ANA) rats, and in the two‐bottle choice self‐administration test, two
H3 receptor antagonists, clobenpropit and thioperamide, significantly
suppressed alcohol intake, whereas the H1 receptor antagonist
mepyramine had no effect on self‐administration. The H3 receptor
agonist R‐α‐methylhistamine increased alcohol self‐administration in
AA rats, suggesting that H3 receptors regulate this behaviour in a bidi-
rectional manner. This finding was surprising and unexpected and
opened up the questions related to the potential mechanisms and
clinical use. Interestingly, the AA rats also had higher histamine H3
receptor expression in two relevant brain areas, the primary motor
cortex and NAcc, and higher tele‐methylhistamine content in the
frontal cortex than that of the ANA rats (Lintunen et al., 2001).Histamine content in AA rat brains was higher than that in ANA rats
in the frontal cortex, septum, hippocampus, and mesencephalon
(Lintunen et al., 2001). Although the activity of the histaminergic sys-
tem was clearly higher in AA than in ANA rats, it is not certain that the
effect of H3 receptor ligands on alcohol self‐administration is medi-
ated by autoreceptors on projections of TMN histaminergic neurons,
because the expression of the H3 receptor is abundant in many
different neurons in relevant brain areas (Panula et al., 2015; Panula
& Nuutinen, 2013).
The effect of H3 receptor antagonists on alcohol consumption or
other AUD‐related behaviours has been reported for a number of H3
receptor antagonists, including thiperamide, clobenpropit, ciproxifan,
JNJ‐39220675, JNJ‐10181475, DL77, and ST1283, consisting of both
imidazole‐ and non‐imidazole‐based molecules (Bahi, Sadek, Nurulain,
Lazewska, & Kiec‐Kononowicz, 2015; Bahi, Sadek, Schwed, Walter, &
Stark, 2013; Nuutinen et al., 2011). These studies also utilized a num-
ber of different drinking models, suggesting that possible caveats
related to a specific method or non‐specific effects of some ligands
do not explain the findings.6 | CLINICAL TREATMENT TRIALS WITH H3
RECEPTOR ANTAGONISTS FOR AUD
Since several companies have produced H3 receptor antagonists
with high potency, good kinetic properties, and no observed toxicity,
two clinical trials have been announced at clinicaltrials.com, but none
have yet been initiated or completed. In addition, several companies have
developed effective drugs, which have been removed from further
development due to adverse side effects or lack of positive effects.
A single centre, randomized, double‐blind, placebo‐controlled par-
allel group Phase 2 study with bavisant (JNJ 31001074) was
announced in 2011 with Janssen Research & Development as spon-
sor. The intention was to study a primary outcome, the urge to drink.
638 PANULABJPThe secondary outcome measures were the number of patients
reporting adverse events; abnormal findings from eye examinations
were performed as a measure of safety and tolerability, as well as vital
signs measurements, electrocardiograms, and clinical laboratory tests.
The planned experimental setup included adult (21–62 years) non‐
treatment‐seeking currently alcohol‐dependent individuals. In the test
setup, the individuals would be shown various computer images and
then presented with either a favourite alcohol‐containing drink or
water (without drinking the offered drink). Study subjects would have
taken one 3 mg tablet of bavisant or matching placebo in the morning
of each day. However, the study was withdrawn before enrolment
following re‐priorization (Panula et al., 2015).
The outcome of a second trial on pitolisant by Bioprojet were
published in 2016. The multisite, double‐blind, placebo‐controlled
study, which was withdrawn by the sponsor before recruitment,
was planned on male or female moderate or severe Diagnostic and
Statistical Manual of Mental Disorders, fifth edition AUD patients
18–65 years of age, who were treatment‐seeking subjects. The
planned primary outcome measure was a decrease in the number
of monthly heavy drinking days (HDDs). Secondary end‐points
included total alcohol consumption from baseline to end of treat-
ment, % of patients without HDDs during the 24 weeks of random-
ized treatment (RT) phase, % of abstinence days during the RT
phase, continuous abstinence duration from baseline during the
24 weeks of RT phase, 4‐week point prevalence abstinence at
the end of treatment, improvement in alcohol biomarkers during
the 24‐week RT phase, craving during the 24‐week RT phase, Beck
depression inventory during the 24‐week RT phase, quality of sleep,
% of patients without HDDs during the open label (OL) follow‐up
period, quality of life (SF‐12) during the RT phase, and quality of
sleep (Pittsburgh Sleep Quality Index) during OL phase. Neither of
these prospective clinical trials was cancelled or discontinued
because of undesired side effects of lack of efficacy but rather they
were withdrawn due to altered company policies.
Based on information on in vivo properties in human subjects
available, the most suitable drug for clinical tests in AUD would be
AZD5213 developed by Astra‐Zeneca. This compound has shown high
occupancy at H3 receptors in human brain, good tolerance after repeated
doses (−14 mg·day‐1) and short (about 5 hr) half‐life (Jucaite et al., 2013).
The short half‐life is particularly important for an H3 receptor antagonist
in clinical use, because drug accumulation in plasma can be significant.
The most likely side effects, which include sleep disturbance, may be less
prominent than with other H3 receptor drugs.7 | CONCLUDING REMARKS: CURRENT
STATE OF RESEARCH AND THE FUTURE
The surprising finding that H3 receptor antagonists can reduce alcohol
intake in AA rats has led to a series of rodent studies. These studies
have found that several H3 receptor antagonists inhibit alcohol intake
in at least three different drinking models and also inhibit alcohol‐
induced reward. Similar findings have been obtained in mice lackingH3 receptors. No evidence of habit‐forming properties of H3 receptor
antagonists have been reported, although these drugs stimulate the
release of several neurotransmitters in different brain regions.
Although the H3 receptor is an autoreceptor, which regulates hista-
mine release, its role in regulating several other transmitters including
GABA and glutamate renders it possible that histamine itself might not
be the key transmitter in th eneuronal circuits involved in AUD. Since
the H3 receptor is expressed in many important brain areas, it is not
obvious where the effects of H3 receptor antagonists occur that then
regulate alcohol‐related behaviours. The most probable site is the
cortico‐striato‐mesencephalic system. Alcohol is known to release
dopamine in the striatum, and H3 receptor antagonists regulate dopa-
mine signalling in the striatum possibly through receptor oligomers
consisting of H3 and dopamine receptors. Experiments on animals
in vivo using, for example, optogenetic inhibition or excitation of spe-
cific neuronal assemblies in freely behaving animals would be needed
to address the potential involvement of these and other areas, for
example, the habenula and amygdala. Drug companies have produced
potentially useful and safe H3 receptor antagonists for clinical testing.
Two clinical trials have been planned to test the use of these drugs to
treat AUD. Both have been withdrawn before starting due to com-
pany policy reasons. The clinical potential of these drugs is thus still
not tested. Such trials would be the obvious next step to open a
new area of application.
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander, Christopoulos et al., 2017; Alexander, Peters et al., 2017).
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